24
Jan

European regulators handed Novartis a major setback in its quest to gain an approval for serelaxin, one of the pharma giant’s top blockbuster prospects which earned “breakthrough” status at the FDA.

…read more

Source: European regulators hand Novartis a big setback on a top blockbuster prospect

    

0 No comments